Breast cancer drug showdown: which one spares your memory?

NCT ID NCT00893061

Completed Knowledge-focused Sponsor: Centre Oscar Lambret Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 3 study looked at how four different hormone therapies (anastrozole, exemestane, letrozole, and tamoxifen) affect memory in postmenopausal women with breast cancer. The 44 participants took one of these drugs for 6 to 12 months, and researchers tested their verbal memory and other thinking skills. The goal was to find out which treatment has the least impact on memory, helping women and their doctors make more informed choices.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: anastrozole, exemestane, letrozole, tamoxifen citrate
What this could lead to: If successful, this study could help doctors choose breast cancer treatments that are less likely to cause memory problems.
What could go wrong: This is a small, completed study with only 44 participants, so results may not apply to all women. It only measured short-term memory changes over 6-12 months.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Centre Eugene Marquis

Rennes, France
Centre Oscar Lambret

Lille, 59020, France
Centre Paul Strauss

Strasbourg, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.